Volpara (ASX:VHT) share price edges lower despite biggest contract win

It seems the medical imaging company’s shares are being dragged lower by broader market weakness.

| More on:
a sonographer monitors an image of a patient's breast on a screen with the patient standing at an imaging device in the background.

Image source: Getty Images

The Volpara Health Technologies Ltd (ASX: VHT) share price is heading south today regardless of the company’s significant positive announcement.

At the time of writing, the healthcare technology company’s shares are down 2.54% to $1.15.

Volpara secures largest-ever contract

According to the company’s announcement, Volpara advised it has signed its biggest contract to date with a leading US outpatient diagnostic imaging provider.

The five-year deal is valued at US$2.15 million which represents an annual recurring revenue (ARR) of US$430,000.

Under the agreement, Volpara will install its Patient Hub software across the customer’s network of imaging centres. The software solution is expected to provide a standardised patient tracking platform that incorporates Volpara Risk and Scorecard.

As such, this will enable the customer to accurately decide the appropriate personalised breast cancer screening pathway for each patient.

Volpara estimates that at least one of its software products is used in the breast cancer screening of more than 33% of women in the US.

Whilst the announcement is extremely positive, it appears the broader All Ordinaries Index (ASX: XAO) is weighing down the Volpara share price. The index is currently down 0.90% to 7,508.7 points.

Volpara group CEO Dr Ralph Highnam commented:

While we would not normally announce individual deals, this is Volpara’s highest-value contract signed to date.

We are experiencing tremendous momentum for our platform in the market as we bring together best-of-breed patient tracking, risk assessment, and density scoring to allow our customers to provide their patients with the individualised care they deserve.

Our platform provides both Volpara and our customers with a significant advantage and is enabling us to seek out opportunities that did not exist even a couple of years ago.

About the Volpara share price

The past 12 months have been disappointing for investors with the company’s shares down 13%. Year-to-date, their losses are further magnified, almost 20% lower over the period.

Based on today’s price, Volpara presides a market capitalisation of roughly $29 million and has approximately 251.3 million shares outstanding.

Should you invest $1,000 in Volpara right now?

Before you consider Volpara, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Volpara wasn't one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended VOLPARA FPO NZ. The Motley Fool Australia owns shares of and has recommended VOLPARA FPO NZ. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares